HER2 Activation Escapes Tyrosine Kinase Inhibitors in Breast Cancer Cells
Author Information
Author(s): Kong Anthony, Calleja Véronique, Leboucher Pierre, Harris Adrian, Parker Peter J., Larijani Banafshé
Primary Institution: Cancer Research UK, London, United Kingdom
Hypothesis
How does HER2 oncogenic function escape inhibition by EGFR tyrosine kinase inhibitors in breast cancer cells?
Conclusion
The study shows that HER2 phosphorylation persists in breast cancer cells treated with EGFR inhibitors due to the activation of alternative HER receptors.
Supporting Evidence
- EGFR tyrosine kinase inhibitors do not fully inhibit HER2 oncogenic function at physiological doses.
- HER2 phosphorylation was not abolished in surviving cells due to activation of alternative HER receptors.
- Combined treatment with Herceptin and Iressa showed greater suppression of HER2 activation.
Takeaway
When treating breast cancer with certain drugs, HER2 can still be active because other receptors help it stay that way, making the treatment less effective.
Methodology
The study used Förster Resonance Energy Transfer (FRET) to monitor HER receptor phosphorylation and classical biochemical analysis to assess the effects of EGFR TKIs.
Limitations
The study primarily focuses on in vitro experiments, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p=0.008
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website